Individualization of maintenance immunosuppressive therapy equalizes acute rejection risk in African American versus non-African American renal allograft recipients.
Lewis
R
R
Department of Urology, Loyola University of Chicago Stritch School of Medicine, Maywood, Illinois 60153, USA.
Coutee
J
J
Kostro
B
B
Calvert
D
D
Cava-Bartsch
C
C
Susskind
B
B
Swies
G
G
Burns
T
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D000465:Algorithms; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D044383:Black People; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology* / Q000517:prevention & control*; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D044469:Racial Groups; D014481:United States; D001741:Black or African American
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3